2496 — Wuhan YZY Biopharma Co Share Price
0.000.00%
Last trade - 00:00- HK$911.09m
- HK$912.24m
- CNY107.81m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 28.03 | ||
| Price to Tang. Book | 28.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -114.46% | ||
| Return on Equity | -123.4% | ||
| Operating Margin | -86.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | 107.81 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Wuhan YZY Biopharma Co Ltd is a China-based company mainly engaged in the discovery, development, and commercialization of new innovative drugs in the field of anti-tumor bispecific antibodies. The Company is committed to developing bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and age-related eye diseases to address the medical needs in oncology and geriatric eye diseases. The Company is still in the research and development stage. The Company's core product M701 is a recombinant BsAb that targets human cancer cell surface antigen EpCAM and human T cell surface antigen CD3. The Company's product pipeline also includes Y101D, Y332, Y225, and others.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 8th, 2010
- Public Since
- September 25th, 2023
- No. of Employees
- 113
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 193,849,200
- Address
- No. 666 Gaoxin Road, WUHAN, 430075
- Web
- https://www.yzybio.com/
- Phone
- +86 2782668988
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 2496
Similar to 2496
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Wuhan YZY Biopharma Co share price?
As of Today at 24:15 UTC, shares in Wuhan YZY Biopharma Co are trading at HK$4.70. This share price information is delayed by 15 minutes.
How has the Wuhan YZY Biopharma Co share price performed this year?
Shares in Wuhan YZY Biopharma Co last closed at HK$4.70 and the price had moved by -36.91% over the past 365 days. In terms of relative price strength the Wuhan YZY Biopharma Co share price has underperformed the FTSE Developed Asia Pacific Index by -36.19% over the past year.
What are the analyst and broker recommendations for Wuhan YZY Biopharma Co?
There is no consensus recommendation for this security.
Find out moreWhat is the Wuhan YZY Biopharma Co dividend yield?
Wuhan YZY Biopharma Co does not currently pay a dividend.
Does Wuhan YZY Biopharma Co pay a dividend?
Wuhan YZY Biopharma Co does not currently pay a dividend.
When does Wuhan YZY Biopharma Co next pay dividends?
Wuhan YZY Biopharma Co does not currently pay a dividend.
How do I buy Wuhan YZY Biopharma Co shares?
To buy shares in Wuhan YZY Biopharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Wuhan YZY Biopharma Co?
As of the previous close price of HK$4.70, shares in Wuhan YZY Biopharma Co had a market capitalisation of HK$911.09m.
Where are Wuhan YZY Biopharma Co shares listed?
Here are the trading details for Wuhan YZY Biopharma Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2496
What kind of share is Wuhan YZY Biopharma Co?
Based on an overall assessment of its quality, value and momentum Wuhan YZY Biopharma Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Wuhan YZY Biopharma Co share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Wuhan YZY Biopharma Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wuhan YZY Biopharma Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -18.89%.
As of the last closing price of HK$4.70, shares in Wuhan YZY Biopharma Co were trading -24.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Wuhan YZY Biopharma Co PE Ratio?
The Wuhan YZY Biopharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$4.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Wuhan YZY Biopharma Co?
We do not have data on Wuhan YZY Biopharma Co's directors